Key Takeaways
- Early human IV studies used roughly 20 to 40 mcg/kg; no RCT has validated a subcutaneous dose for sleep in healthy adults.
- The most cited community subcutaneous dose is 100 to 400 mcg administered 30 to 60 minutes before sleep onset.
- DSIP's plasma half-life after IV dosing is measured in minutes, yet sleep-architecture effects in small trials lasted several hours, suggesting indirect CNS signaling rather than direct sedation.
- Nasal spray bioavailability for a nonapeptide the size of DSIP is theoretically poor without permeation enhancers; effective nasal dose cannot currently be stated with confidence.
- Purity of commercially available research-grade DSIP varies substantially; HPLC purity above 98% and an endotoxin test on the certificate of analysis are minimum credibility markers.
What is the correct DSIP dosage?
Table of Contents
- Evidence Ledger: What Each Major Claim Is Based On
- DSIP Mechanism With Numbers
- DSIP Dosage for Sleep: Human Data vs. Community Protocol
- DSIP Peptide Dosing Chart
- DSIP Nasal Spray Dosage: The Bioavailability Problem
- DSIP Protocol: Cycling and Timing
- What Most Pages Get Wrong About DSIP Dosing
- Chemistry Behind the Rules: Why Dose Timing and Storage Matter
- Honest Head-to-Head: DSIP vs. Alternatives for Sleep
- Operational and Label Literacy: Reading a COA, Reconstitution Math
- FAQ
- Sources
1. Evidence Ledger: What Each Major Claim Is Based On
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| DSIP reduces sleep latency and increases slow-wave sleep | Small human trials (IV, no placebo control), early 1980s; animal studies | Positive trend | Low |
| IV dose of ~20-40 mcg/kg produces physiological effects | Human pharmacokinetic/pharmacodynamic studies (Schneider-Helmert et al.) | Positive, modest | Low-Moderate |
| Plasma half-life after IV dosing is minutes | Human PK study | Established direction | Moderate |
| Subcutaneous 100-400 mcg is effective for sleep | Community reports; no controlled trial | Anecdotal positive | Very Low |
| Nasal spray achieves meaningful systemic levels | No published bioavailability study for DSIP nasal route | Unknown | Very Low |
| DSIP modulates corticotropin and LH release | Animal studies; limited human neuroendocrine data | Modulatory | Low |
| Oral DSIP is inactive (proteolytic degradation) | Biochemical mechanism; no counterevidence | Inactive expected | High (mechanistic) |
| Purity of research-grade DSIP is variable | Analytical testing reports from independent labs | Concern confirmed | Moderate |
2. DSIP Mechanism With Numbers
Delta sleep-inducing peptide (DSIP) is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, molecular weight approximately 848 Da) first isolated from rabbit cerebral venous blood during slow-wave sleep by Monnier and colleagues in 1977. It is found endogenously in both the CNS and periphery, including the hypothalamus, pituitary, and gut.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Key mechanism facts:
- Sleep architecture modulation: In small human studies by Schneider-Helmert and Schoenenberger (1983, 1984), IV DSIP appeared to increase stage 3 and 4 (slow-wave) sleep fractions compared to baseline nights. Sample sizes were small (generally under 20 subjects) and controls were not always placebo-blinded.
- Neuroendocrine interaction: Animal data suggest DSIP modulates ACTH, LH, and somatostatin release; it does not act as a simple GABA-A agonist the way benzodiazepines do, which is mechanistically important for understanding its side-effect profile differences.
- Half-life paradox: IV plasma clearance is rapid (on the order of minutes in human PK studies). Yet sleep-promoting effects in trials lasted through the night. This suggests DSIP either crosses the blood-brain barrier during its brief plasma window, binds to a receptor with prolonged downstream signaling, or triggers endogenous mediator release. The mechanism is not fully resolved.
- What this does NOT prove: A short IV half-life does not automatically predict subcutaneous pharmacokinetics. SQ injection may create a depot with slower absorption, potentially altering both peak concentration and duration. No subcutaneous PK study in humans has been published.
3. DSIP Dosage for Sleep: Human Data vs. Community Protocol
The controlled human data come primarily from Swiss researchers in the early-to-mid 1980s. Schneider-Helmert and colleagues administered DSIP intravenously to patients with chronic insomnia and to normal volunteers, using doses in the range of approximately 20 to 40 mcg per kilogram body weight. A 70 kg adult at 25 mcg/kg receives 1,750 mcg IV total.
Community subcutaneous protocols use a different dose structure: flat doses of 100 to 600 mcg, most commonly 200 to 300 mcg, injected subcutaneously 30 to 60 minutes before sleep. Whether this route achieves comparable CNS exposure to the IV doses studied is unknown. The ratio is not 1:1 for most peptides, and for DSIP specifically no crossover PK data exist.
4. DSIP Peptide Dosing Chart
| Route | Dose Range Cited in Literature or Community | Timing | Evidence Basis | Confidence |
|---|---|---|---|---|
| Intravenous (human trials) | ~20 to 40 mcg/kg body weight | Evening; bedtime | Small human trials (Schneider-Helmert) | Low-Moderate |
| Subcutaneous (community) | 100 to 600 mcg; most common 200 to 300 mcg | 30 to 60 min before sleep | Community convention; no RCT | Very Low |
| Intranasal spray (community) | 100 to 300 mcg per spray administration | 30 to 45 min before sleep | Formulation convention; no bioavailability study | Very Low |
| Oral | Not applicable | N/A | Expected proteolytic degradation; no supporting data | Not recommended |
Body weight adjustment: If extrapolating from the IV human trial dose as a rough ceiling reference only, a 70 kg adult at 25 mcg/kg would equal approximately 1,750 mcg IV total. Community SQ doses of 200 to 300 mcg are substantially lower in absolute terms, though route difference makes direct comparison unreliable.
5. DSIP Nasal Spray Dosage: The Bioavailability Problem
DSIP nasal spray products exist in the compounding market, often at concentrations of 1 to 2 mg/mL delivering 100 to 300 mcg per spray. The marketing logic is that intranasal delivery bypasses gastrointestinal degradation and may offer partial olfactory-nerve access to the CNS.
The practical problem: DSIP at 848 Da sits above the 500 Da rule of thumb for good passive nasal absorption. Small peptides can achieve meaningful nasal bioavailability (salmon calcitonin, desmopressin), but these typically require adjuvants or have unusually favorable transport characteristics. No published bioavailability study exists for intranasal DSIP in humans or animals. Absorption could be negligible without a permeation enhancer, or it could be partial. The honest answer is that an effective intranasal DSIP dose cannot be stated with scientific confidence at this time.
6. DSIP Protocol: Cycling and Timing
Cycle length: Community protocols most commonly run 5 to 20 consecutive nights, then pause for at least an equal duration. The rationale is to avoid potential tachyphylaxis or receptor downregulation, though neither phenomenon has been formally demonstrated for DSIP.
Timing within the day: Every protocol and available study used evening administration. DSIP has a reported endogenous circadian pattern with higher plasma levels in the evening. Dosing in the morning or midday has not been studied for sleep applications and is not expected to be useful.
Combination use: Some practitioners combine DSIP with Epitalon (a tetrapeptide with proposed circadian and pineal effects) or low-dose Selank. No controlled interaction or combination dosing data exist. Stacking increases the number of unknown variables and should be approached with proportionate caution.
Frequency: Nightly dosing for the duration of the cycle is most common. Some protocols use every-other-night dosing to reduce potential habituation. Neither approach has been tested in controlled trials.
7. What Most Pages Get Wrong About DSIP Dosing
Most commodity pages treat the community subcutaneous dose (200 to 300 mcg) as if it were derived from clinical data. It is not. The IV doses studied in humans in the 1980s were not subcutaneous, and the conversion to SQ is not established. Pages that present a single authoritative-sounding dose number without qualifying the evidence basis are misleading the reader.
A second omission: the half-life caveat. Many pages correctly note DSIP's short half-life in passing, then proceed as if a once-nightly SQ injection definitively produces the same effects as the IV administration studied. The depot kinetics of SQ DSIP could produce a lower peak but longer trough, a different exposure profile, or both. This changes the pharmacological story substantially.
Third: the nasal spray route is presented as equivalent or superior to SQ by many vendors. No evidence supports this. The size and hydrophilicity of the DSIP nonapeptide makes passive nasal absorption genuinely uncertain. Until a bioavailability study exists, anyone presenting a confident intranasal dose is guessing.
8. Chemistry Behind the Rules: Why Dose Timing and Storage Matter
Why store lyophilized DSIP cold and reconstituted DSIP refrigerated: DSIP contains a tryptophan residue (position 1) that is susceptible to oxidation, particularly at the indole ring. Elevated temperature and exposure to light accelerate this oxidation. The glycine residues reduce steric protection. In reconstituted aqueous solution, hydrolysis of peptide bonds is a competing degradation pathway that is temperature-dependent. Refrigeration at 2 to 8 degrees Celsius slows both oxidation and hydrolysis. Freeze-thaw cycling of reconstituted solution can cause aggregation and should be avoided; aliquot before freezing if longer storage is needed.
Why bacteriostatic water, not sterile water: Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits microbial growth in opened vials used across multiple doses. Sterile water has no preservative; once opened a sterile-water reconstituted vial should be used immediately or within 24 hours. For multi-dose subcutaneous use, bacteriostatic water extends usable life to approximately 28 days when refrigerated.
Why not mix with vitamin C or acidic solutions: Tryptophan-containing peptides can be degraded by the reducing environment created by ascorbic acid. This is not a reason to avoid vitamin C supplementation generally; it means do not co-administer in the same syringe or solution.
9. Honest Head-to-Head: DSIP vs. Alternatives for Sleep
| Agent | Mechanism | RCT Evidence | Approved | Where DSIP Wins | Where DSIP Loses |
|---|---|---|---|---|---|
| Zolpidem | GABA-A positive allosteric modulator | Large, Phase III, replicated | Yes (Schedule IV) | No rebound insomnia reported; potentially different receptor mechanism | Vastly inferior evidence base; no approval; unknown SQ PK |
| Eszopiclone | GABA-A modulator (cyclopyrrolone) | Multiple RCTs, long-term data | Yes | Theoretical: no dependence scheduling equivalent | Inferior evidence; no head-to-head trials |
| Melatonin | MT1/MT2 receptor agonist; circadian | Numerous RCTs; moderate effect size | OTC (US); Rx in EU | DSIP may have additive mechanism; both are endogenous | Melatonin has far more evidence, lower cost, established dosing |
| Ramelteon | MT1/MT2 selective agonist | Multiple RCTs | Yes (Rx) | None established | Approved drug with replicated trials vs. unapproved peptide |
| Epitalon (stacked) | Pineal/telomerase modulation proposed | Animal and small Russian studies only | No | Theoretical circadian synergy | Both are low-evidence; stacking doubles uncertainty |
DSIP does not beat any approved sleep medication on the evidence. Its theoretical interest lies in an endogenous neuropeptide mechanism distinct from GABA-A modulation, which may translate to a different tolerability profile, but this has not been demonstrated in controlled trials.
10. Operational and Label Literacy: COA Reading and Reconstitution Math
Reading a Certificate of Analysis for DSIP
- HPLC purity: Look for greater than 98% by HPLC. Anything below 95% is a concern for a research compound intended for injection.
- Molecular weight confirmation: Mass spectrometry should confirm the peak at approximately 848 Da (or the sodium adduct at approximately 870 Da). This confirms identity, not just purity.
- Endotoxin testing: Critical for injectable use. Should be below 1 EU/mg. Many cheap research peptides skip this test. Absence of endotoxin testing on a COA is a red flag for injectable products.
- Amino acid analysis: Confirms the correct sequence. Not all COAs include this; its presence indicates a higher-quality supplier.
Reconstitution Math
| Vial Size | Bacteriostatic Water Added | Concentration | Volume for 200 mcg Dose | Volume for 300 mcg Dose |
|---|---|---|---|---|
| 2 mg (2000 mcg) | 1.0 mL | 2000 mcg/mL | 0.10 mL (10 units on U100 syringe) | 0.15 mL (15 units) |
| 2 mg (2000 mcg) | 2.0 mL | 1000 mcg/mL | 0.20 mL (20 units) | 0.30 mL (30 units) |
| 5 mg (5000 mcg) | 2.5 mL | 2000 mcg/mL | 0.10 mL (10 units) | 0.15 mL (15 units) |
Injection site: Subcutaneous injection into the abdomen (pinching a fold of skin) is standard for peptide administration. Rotate sites to reduce local irritation.
Signs of degraded product: Discard any vial where the lyophilized powder is brown or yellow before reconstitution, where reconstituted solution is cloudy or has visible particles, or where the solution has a yellow or brown tint. These indicate oxidation, aggregation, or contamination.
FAQ
What is the standard DSIP dosage for sleep?
Early human studies used intravenous doses ranging from approximately 20 to 40 micrograms per kilogram of body weight. Community-reported subcutaneous protocols typically fall between 100 and 600 micrograms per dose, administered 30 to 60 minutes before bed. No placebo-controlled RCT has validated a specific subcutaneous dose for sleep induction in healthy adults.
How much DSIP should I take per injection?
The most commonly referenced subcutaneous dose is 100 to 400 micrograms injected 30 to 60 minutes before sleep. Lower end doses (100 mcg) are typically used for initial administration. There is no human RCT establishing an optimal subcutaneous dose.
What is the DSIP nasal spray dosage?
Typical compounded DSIP nasal spray formulations deliver 100 to 300 micrograms per spray. Nasal bioavailability for DSIP has not been formally studied; transmucosal absorption of larger peptides is generally poor without permeation enhancers, so effective dose via this route is unknown.
How long should a DSIP protocol last?
Community protocols typically run 5 to 20 nights consecutively, then cycle off for an equal or longer period. Sustained nightly use beyond a few weeks has no controlled safety data in humans, and tachyphylaxis has not been formally studied but is a theoretical concern.
When should DSIP be taken?
Available human data used evening or bedtime administration. Most protocols call for dosing 30 to 60 minutes before intended sleep onset, consistent with DSIP's reported circadian peaking in the evening. Daytime dosing has not been studied for sleep applications.
Can DSIP be combined with other sleep peptides?
Some practitioners stack DSIP with Epitalon or low-dose Selank. No controlled data exist on combination protocols. Additive sedation with other CNS-active compounds is a theoretical risk. Stacking is speculative and increases unknown variable burden.
Is DSIP safe at the doses commonly used?
Early human studies reported minimal acute adverse effects at intravenous doses of 20 to 40 mcg/kg. Long-term or high-dose subcutaneous safety data in humans are absent. The peptide has no FDA approval; purity of commercially available research-grade DSIP is highly variable.
What does a degraded DSIP vial look like?
Lyophilized DSIP should appear as a white or off-white powder. Reconstituted solution should be clear and colorless. Visible particulates, cloudiness, or a yellow or brown tint in solution indicate degradation or contamination and the vial should be discarded.
How do I reconstitute DSIP for injection?
Add bacteriostatic water slowly along the vial wall, do not shake. A common starting dilution is 1 mL bacteriostatic water into a 2 mg vial, yielding 2000 mcg/mL. For a 200 mcg dose, draw 0.10 mL. Refrigerate after reconstitution and use within approximately 28 days.
How does DSIP compare to approved sleep medications?
Approved agents like zolpidem and eszopiclone have large RCT databases confirming efficacy. DSIP lacks any Phase III trial. DSIP may offer a different mechanism (endogenous neuropeptide modulation) and a potentially cleaner side-effect profile, but this remains unproven at a controlled-trial level.
Does DSIP work via oral administration?
DSIP is a nonapeptide (9 amino acids) that would be rapidly degraded by gastrointestinal proteases. No evidence supports meaningful oral bioavailability. Oral DSIP products are not expected to deliver active peptide systemically.
What is the molecular weight and half-life of DSIP?
DSIP has a molecular weight of approximately 848 daltons. Its plasma half-life after intravenous administration in early human studies was short, on the order of minutes, though downstream effects on sleep architecture appeared to persist longer. Subcutaneous half-life has not been formally characterized.
Sources
- Monnier M, Dudler L, Gaechter R, et al. The delta sleep inducing peptide (DSIP): comparative properties of the original and synthetic nonapeptide. Experientia. 1977;33(4):548-552.
- Schneider-Helmert D, Schoenenberger GA. Effects of DSIP in man. Multivariable assessment of sleep, mood and performance. Neuropsychobiology. 1983;9(2-3):197-206.
- Schneider-Helmert D. DSIP in sleep disturbances. European Neurology. 1984;23(5):358-363.
- Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram-sleep-inducing peptide. Proceedings of the National Academy of Sciences USA. 1977;74(3):1282-1286.
- Graf MV, Hunter CA, Kastin AJ. Presence of delta-sleep-inducing peptide in human milk. Journal of Clinical Endocrinology and Metabolism. 1984;59(1):127-132.
- Iyer KS, McCann SM. Delta sleep inducing peptide (DSIP) stimulates the release of LH but not FSH via a hypothalamic site of action in the rat. Brain Research Bulletin. 1987;19(5):535-538.
- Khvatova EM, Samartzev VN, Zagoskin PP, Prudchenko IA, Mikhaleva II. Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency. Peptides. 2003;24(2):307-311.
- Steiger A. Neurochemical regulation of sleep. Journal of Psychiatric Research. 2007;41(7):537-552. (Reviews neuropeptide roles in sleep including DSIP.)
- Sudakov SK, Bogdanova NG, Nazarova GA. DSIP-like immunoreactivity in rat brain structures and peripheral organs. Bulletin of Experimental Biology and Medicine. 2001;131(3):237-239.
Footer Disclaimers
Platform: FormBlends provides educational content for informational purposes only. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or research compound.
Research Compound: DSIP is not approved by the FDA for any therapeutic indication. It is sold for research purposes only. It is not intended for human consumption except as part of a supervised clinical investigation.
Results: Individual results vary. The information presented reflects available published literature and community convention. Many claims about DSIP are based on low-quality or very old evidence. FormBlends does not guarantee any outcome.
Trademark: All product names and trademarks mentioned are the property of their respective owners. FormBlends is not affiliated with any peptide manufacturer or compounding pharmacy mentioned or implied in this article.